Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 287

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 14
Chunk 287
---
 However, the Company has not asked the Sponsor to reserve for such indemnification obligations,
nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believe
that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure its stockholders that the Sponsor
would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by
third parties including, without limitation, claims by vendors and prospective target businesses. The Company will seek to reduce the
possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors,
service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the
Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

    F-8

Note
1 – Description of Organization and Business Operations, Going Concern and Basis of Presentation (Continued)

Business
Combination

On
September 16, 2024, the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Longevity Biomedical,
Inc., a Delaware corporation (“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary
of the Company (“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative.

The
Merger Agreement provides that the parties thereto will enter into a business combination transaction (the “Longevity Business
Combination” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant
to which, among other things, (i) Longevity will consummate Target Acquisitions (as defined therein) upon the terms and subject to conditions
set forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation
of the Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving
company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the Company. At the closing of the Transactions
(the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.” and the Company’s
common stock is expected to list on the NASDAQ Stock Market under the ticker symbol “LBIO.”

The
consum